Compare Stocks → Now Open: Crypto emergency update (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BIORNASDAQ:CELCNASDAQ:DMTK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIORBiora Therapeutics$0.60-6.3%$0.98$0.58▼$6.70$23.04M1.09451,728 shs519,041 shsCELCCelcuity$16.39-3.6%$17.55$8.39▼$22.19$499.08M0.78215,480 shs200,027 shsDMTKDermTech$0.59$0.87$0.59▼$4.58$20.46M2.52318,300 shs256,375 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIORBiora Therapeutics-6.63%-14.95%-49.62%-34.27%-77.80%CELCCelcuity-3.64%-16.76%-8.94%+11.04%+62.28%DMTKDermTech-0.17%-10.99%-13.99%-53.10%-86.63%You’re invited: Biggest crypto event of 2024 (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIORBiora Therapeutics0.8187 of 5 stars0.03.00.00.03.22.50.6CELCCelcuity2.8879 of 5 stars3.53.00.00.03.24.20.0DMTKDermTech0.75 of 5 stars3.31.00.00.00.60.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIORBiora Therapeutics3.00BuyN/AN/ACELCCelcuity3.00Buy$29.0076.94% UpsideDMTKDermTech2.50Moderate Buy$3.25449.92% UpsideCurrent Analyst RatingsLatest DMTK, CELC, and BIOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.003/28/2024CELCCelcuityCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $25.003/28/2024CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $24.003/28/2024CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.003/5/2024DMTKDermTechStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$2.50 ➝ $1.502/22/2024CELCCelcuityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIORBiora Therapeutics$4K5,378.11N/AN/A($3.73) per share-0.16CELCCelcuityN/AN/AN/AN/A$5.48 per shareN/ADMTKDermTech$15.30M1.34N/AN/A$1.67 per share0.35Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIORBiora Therapeutics-$124.11M-$8.57N/AN/AN/AN/AN/A-147.40%5/20/2024 (Estimated)CELCCelcuity-$63.78M-$2.69N/AN/AN/AN/A-54.74%-39.13%5/20/2024 (Estimated)DMTKDermTech-$100.89M-$3.14N/AN/AN/A-659.57%-123.96%-67.94%5/2/2024 (Estimated)Latest DMTK, CELC, and BIOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023DMTKDermTech-$0.54-$0.56-$0.02-$0.56$4.05 million$3.92 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIORBiora TherapeuticsN/AN/AN/AN/AN/ACELCCelcuityN/AN/AN/AN/AN/ADMTKDermTechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIORBiora TherapeuticsN/A0.300.30CELCCelcuity0.2613.4313.43DMTKDermTechN/A4.594.52OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIORBiora Therapeutics43.74%CELCCelcuity63.33%DMTKDermTech20.45%Insider OwnershipCompanyInsider OwnershipBIORBiora Therapeutics23.18%CELCCelcuity24.29%DMTKDermTech5.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBIORBiora Therapeutics5835.88 million27.57 millionOptionableCELCCelcuity5530.45 million23.06 millionOptionableDMTKDermTech20634.62 million32.86 millionOptionableDMTK, CELC, and BIOR HeadlinesSourceHeadlineDermTech to Slash 56% of Workforce, Explore Optionsmarketwatch.com - April 18 at 8:56 PMDermTech to Lay off 100 Employees in Restructuring, Explore Strategic Alternatives360dx.com - April 18 at 8:56 PMDermTech exploring strategic alternatives, cutting 56% of staffmsn.com - April 18 at 8:56 PMDermTech to Explore Strategic Alternatives and Implement Restructuring Planbusinesswire.com - April 18 at 4:15 PMDermTech, Inc. (DMTK)finance.yahoo.com - April 17 at 6:34 PMDermTech (NASDAQ:DMTK) Trading Down 0.9%americanbankingnews.com - April 17 at 2:20 AMDermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatologybusinesswire.com - March 8 at 8:05 AMStephens cuts DermTech stock target to $1.50, keeps Equal Weight ratinginvesting.com - March 7 at 10:18 AMDermTech, Inc. (NASDAQ:DMTK) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 2 at 9:48 AMDermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimateszacks.com - February 29 at 6:26 PMRecap: DermTech Q4 Earningsbenzinga.com - February 29 at 6:05 PMDermTech Reports Fourth-Quarter 2023 Financial Resultsbusinesswire.com - February 29 at 4:01 PMDermTech Q4 2023 Earnings Previewmsn.com - February 28 at 9:12 PMDermTech Announces Release Date for Fourth-quarter 2023 Financial Resultsfinance.yahoo.com - February 13 at 12:52 PMDermTech, the San Diego biotech making a skin-cancer detecting patch, cuts 15% of workforcesandiegouniontribune.com - February 6 at 6:49 PMDermTech International Registered Shsmarkets.businessinsider.com - February 1 at 10:27 AMDermTech to Cut Workforce by 15%, Six Months After Round of Layoffsmarketwatch.com - January 31 at 6:32 PMDermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operationsfinance.yahoo.com - January 31 at 6:32 PMDermTech study finds melanoma test effective for all skin typesmsn.com - January 18 at 4:01 PMDermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Typesfinance.yahoo.com - January 18 at 9:27 AMDermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assayfinance.yahoo.com - January 16 at 10:25 AMDermTech Shares Rise 14% After Positive Results in Melanoma Test Studymarketwatch.com - January 8 at 3:46 PMDermTech stock rallies 18% on positive study for melanoma testseekingalpha.com - January 8 at 10:45 AMDermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)finance.yahoo.com - January 8 at 10:45 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiora TherapeuticsNASDAQ:BIORBiora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.CelcuityNASDAQ:CELCCelcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.DermTechNASDAQ:DMTKDermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.